Developer docs
API playgroundTry for free, no card

Search company profiles

Zymeworks

Full company profile

uuid0000m2r

Namestring
Zymeworks
Legal namestring
Zymeworks BC Inc.
Websiteurl
zymeworks.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Zymeworks is a Vancouver-headquartered, publicly traded (NASDAQ: ZYME) biotechnology company that has restructured itself as a royalty-driven organization developing antibody-based therapeutics for difficult-to-treat cancers and inflammatory diseases. The company operates a proprietary antibody engineering stack spanning four platforms: Azymetric (heterodimeric bispecific antibody technology clinically validated through the FDA-approved zanidatamab), EFECT (Fc-region effector function modulation), TriTCE (trispecific T cell engagers with conditional CD28 co-stimulation), and ZymeLink ADC payloads (topoisomerase-1 inhibitor, auristatin, and hemiasterlin warheads paired with site-specific conjugation). Its sole commercial product is Ziihera (zanidatamab-hrii), a HER2-directed bispecific antibody approved in the US, EU (conditional), and China for previously treated HER2-positive biliary tract cancer, with a near-term first-line HER2-positive gastroesophageal adenocarcinoma approval decision expected August 25, 2026.

The pipeline includes four clinical-stage assets: ZW191 (FRα-targeting ADC with FDA Fast Track designation for platinum-resistant ovarian cancer, showing 78.6% confirmed ORR in FRα-positive patients in Phase 1), ZW251 (GPC3-targeting ADC for hepatocellular carcinoma), ZW209 (DLL3-targeting trispecific T cell engager for small cell lung cancer), and ZW220 (NaPi2b-targeting ADC). Zymeworks also has ZW1528, an IL-4Rα x IL-33 bispecific for respiratory inflammation/COPD, expanding into non-oncology indications. Partnered assets include pasritamig (CD3 x KLK2 bispecific), which Johnson & Johnson is advancing through Phase 3 for castration-resistant prostate cancer.

Zymeworks generates revenue through tiered royalties (10-20% on Ziihera) and milestone payments (up to $1.36 billion potential from Jazz/BeOne, up to $434 million from J&J) rather than direct commercialization. Three global pharma partners handle manufacturing, regulatory submissions, and sales: Jazz Pharmaceuticals (US/global Ziihera), BeOne Medicines (China/APAC), and Johnson & Johnson (pasritamig globally). The company executed a $250 million non-recourse royalty-backed note financing from Royalty Pharma in March 2026 and authorized a $125 million share repurchase program, holding $403.8 million in cash and equivalents as of Q1 2026 with runway beyond 2028.

Short descriptiontext

Zymeworks is a Vancouver-based, publicly traded royalty-driven biotechnology company developing antibody-based therapeutics (bispecifics, ADCs, T cell engagers) for difficult-to-treat cancers, with FDA-approved Ziihera for biliary tract cancer and a pipeline of clinical-stage ADC and TCE assets partnered with Jazz, BeOne, and J&J.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, bispecific antibodies, antibody-drug conjugates, oncology drug development, biotechnology licensing
Industry4 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Royalty Revenue from Ziihera
TypeLicensing Royalties
Description

Zymeworks receives tiered worldwide royalties between 10% to 20% on Ziihera (zanidatamab-hrii) sales from Jazz Pharmaceuticals, and tiered royalties up to 19.5% from BeOne Medicines territories. Royalty Pharma holds 30% of Ziihera royalties under the $250M financing deal.

zymeworks.com
2Royalty Revenue from Pasritamig
TypeLicensing Royalties
Description

Zymeworks receives tiered worldwide royalties in the mid-single digit percentages from Johnson & Johnson's pasritamig (JNJ-78278343) sales for castration-resistant prostate cancer.

zymeworks.com
3Milestone Payments
TypeLicensing Royalties
Description

Zymeworks earns milestone payments upon achievement of regulatory approvals and commercial milestones. Up to $1.36B potential milestone payments from Jazz/BeOne for Ziihera across US, EU, Japan, and China. Additional milestones from J&J partnerships and GSK collaborations. A $250M milestone payment from Jazz is expected upon FDA approval in August 2026.

zymeworks.com
4Royalty-Backed Financing
TypeLicensing Royalties
Description

$250M non-recourse royalty-backed note financing from Royalty Pharma, with repayments secured by 30% of worldwide tiered royalties on Ziihera. Royalty Pharma ceases receiving royalties once cumulative payments reach 1.65x the note amount by Dec 31, 2033, or 1.925x at any time thereafter.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Azymetric
Description

Heterodimeric antibody technology platform enabling transformation of monospecific antibodies into multispecific antibodies with alternative target binding formats.

zymeworks.com
+4 more records
Core offering1 text field

Zymeworks is a clinical-stage biopharmaceutical company that designs and develops novel antibody-based therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs), for difficult-to-treat cancers. The company uses proprietary platforms such as Azymetric, EFECT, TriTCE, and topoisomerase-1 inhibitor payload technologies to engineer its pipeline candidates (e.g., Ziihera/zanidatamab, ZW191, ZW251, ZW220, ZW209, ZW1528) and licenses these candidates and platforms to large pharmaceutical partners (Jazz Pharmaceuticals, BeOne Medicines, Johnson & Johnson, GSK) for global development and commercialization in exchange for royalties and milestone payments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 78.6% confirmed objective response rate in FRα-positive platinum-resistant ovarian cancer patients (ZW191 Phase 1)
+5 more records
Product overview1 text field

Zymeworks is a royalty-driven biotechnology company that has transformed from a clinical-stage biotech into a healthcare asset management organization. The company manages a portfolio of licensed products and develops novel multifunctional biotherapeutics. Its core approved product is Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody for biliary tract cancer. The proprietary pipeline includes multiple antibody-drug conjugates (ZW191, ZW251, ZW220) targeting different tumor antigens using topoisomerase-1 inhibitor payloads, and trispecific T cell engagers (ZW209) and bispecific antibodies (ZW1528) for oncology and inflammatory diseases. These programs are supported by proprietary technology platforms including Azymetric (bispecific antibody engineering), EFECT (effector function modulation), TriTCE (T cell engager with costimulation), and ADC payload technologies. The company generates revenue through royalties and milestone payments from partners including Jazz Pharmaceuticals, BeOne Medicines, and Johnson & Johnson.

Product and service11 records
1Ziihera (zanidatamab-hrii)
CategoryApproved Drug
Description

A bispecific HER2-directed antibody approved by the FDA for treating adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Also in development for gastroesophageal adenocarcinoma and other HER2-expressing cancers.

2ZW191
CategoryClinical Stage Asset - Phase 1
Description

A folate receptor alpha (FRα)-targeting antibody-drug conjugate using a topoisomerase-1 inhibitor payload (ZD06519) for treatment of advanced solid tumors including ovarian, endometrial, and lung cancers. FDA Fast Track designation granted for platinum-resistant ovarian cancer.

3ZW251
CategoryClinical Stage Asset - Phase 1
Description

A glypican-3 (GPC3)-targeting ADC using a topoisomerase-1 inhibitor payload for treatment of hepatocellular carcinoma (HCC).

4ZW220
CategoryPreclinical Asset
Description

A sodium-dependent phosphate transporter 2b (NaPi2b)-targeting ADC using a topoisomerase-1 inhibitor payload for treatment of ovarian, lung, and pancreatic cancers; IND-ready.

5ZW209
CategoryPreclinical Asset
Description

A DLL3-targeting trispecific T cell engager (TriTCE) with conditional CD28 co-stimulation for treatment of small cell lung cancer and other DLL3-expressing cancers.

6ZW1528
CategoryPreclinical Asset
Description

An IL-4Rα x IL-33 bispecific antibody designed to address respiratory inflammation including mixed-type COPD by inhibiting multiple cytokine pathways.

7JNJ-78278343 (pasritamig)
CategoryPartnered Asset - Phase 3
Description

A CD3 x KLK2 bispecific T cell engager being developed and commercialized by Johnson & Johnson for castration-resistant prostate cancer; eligible for up to $434M in milestones plus tiered worldwide mid-single digit royalties.

8Azymetric Platform
CategoryTechnology Platform (Licensed)
Description

A heterodimeric antibody technology enabling engineering of multispecific antibodies that simultaneously bind multiple distinct targets, supporting formats including Fabs, scFvs, and VHHs; available for partnership/licensing.

9EFECT Platform
CategoryTechnology Platform (Licensed)
Description

Effector Function Enhancement and Control Technology enabling modification of antibody Fc region to selectively modulate interactions with Fc-gamma receptors and complement (C1q) to enhance or negate immune responses.

10TriTCE Co-Stim Platform
CategoryTechnology Platform (Licensed)
Description

Trispecific T cell engager platform with integrated conditional cis CD28 co-stimulation providing T cells with signal 1 (CD3) and signal 2 for enhanced safety and antitumor activity; transferable to diverse targeting strategies.

11Topoisomerase 1 Inhibitor ADC Technology (ZD06519)
CategoryTechnology Platform (Licensed)
Description

Camptothecin-based payload specifically designed for ADC use with moderate potency and strong bystander activity, paired with a traceless, plasma-stable, cleavable peptide linker enabling DAR up to 8.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-06-09
Description

Strategic collaboration for development of bispecific antibodies using Zymeworks' Azymetric platform. Zymeworks eligible for up to $921.8M in potential milestone payments plus tiered worldwide royalties on sales. GSK collaboration achieved $14M milestone in February 2025.

Strategic tierCore/FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-11-28
Description

Licensing agreement for zanidatamab (Ziihera) where Jazz holds US commercialization rights and pays tiered royalties (10-20%) plus milestone payments up to $1.36B. Jazz confirmed opt-in in December 2022 and is pursuing FDA approval for first-line HER2+ gastroesophageal adenocarcinoma with PDUFA date of August 25, 2026.

Strategic tierCore/FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-11-28
Description

Licensing agreement for zanidatamab where BeOne Medicines holds commercialization rights in China and Asia-Pacific territories, paying tiered royalties up to 19.5% of net sales. BeOne received NMPA approval for HER2-high biliary tract cancer in China and is pursuing additional approvals for gastroesophageal adenocarcinoma.

4Johnson & Johnson (Janssen)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-10-25
Description

Collaboration for development of bispecific antibodies including pasritamig (JNJ-78278343, CD3 x KLK2) targeting castration-resistant prostate cancer in Phase 3. Zymeworks eligible for up to $434M in milestones and tiered worldwide royalties in mid-single digit percentages. Peak sales opportunity referenced by J&J exceeds $1-5B.

zymeworks.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Pyxis Oncology develops ADCs and immunotherapies for difficult-to-treat cancers, with a focus on novel payload and linker technology. Comparable to Zymeworks' emerging ADC pipeline with similar target patient populations in solid tumors.

TypeDirect peer
Description

Mersana is a clinical-stage ADC company developing novel payloads and linkers for oncology applications. Directly comparable to Zymeworks' ADC platform (ZW191, ZW251, ZW220) and novel topoisomerase-1 inhibitor payload approach.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptide-based therapeutics including toxin conjugates (Bicyclic ADC platform) for oncology, comparable to Zymeworks' ZW191/ZW251 ADC programs. Both companies target solid tumors with novel payload and conjugation approaches.

TypeBroad incumbent
Description

Seagen (acquired by Pfizer for $43B) is a leading ADC company with multiple approved products (Adcetris, Padcev, Tukysa, Tivdak) and represents an established incumbent in the ADC space comparable to Zymeworks' ADC pipeline focus.

TypeDirect peer
Description

MacroGenics develops bispecific antibodies and antibody-based therapeutics for cancer, sharing Zymeworks' focus on multispecific antibody platforms. Both companies target oncology with proprietary antibody engineering platforms and similar therapeutic indications including solid tumors.

TypeBroad incumbent
Description

ImmunoGen (acquired by AbbVie) pioneered ADC technology and markets Elahere, an FRα-targeting ADC for platinum-resistant ovarian cancer. Directly competes with Zymeworks' ZW191 in the same indication with similar target and mechanism.

TypeEmerging player
Description

Bolt Biotherapeutics develops immune-stimulating ADCs (ISACs) combining tumor-targeting antibodies with immune agonists. Shares Zymeworks' focus on novel ADC payloads and difficult-to-treat solid tumor indications.

TypeBroad incumbent
Description

Daiichi Sankyo developed Enhertu (trastuzumab deruxtecan), the leading HER2 ADC that competes with Ziihera in HER2-positive cancers. Represents a broad incumbent with overlapping HER2 oncology franchise relevant to Zymeworks' partnered bispecific asset.

TypeDirect peer
Description

Genmab is a leading bispecific antibody developer (Duobody platform) with multiple approved and clinical-stage products including bispecifics partnered with large pharma. Directly comparable to Zymeworks' Azymetric-based bispecific approach and royalty/partnership business model.

TypeEmerging player
Description

Innovent is a Chinese biopharmaceutical company developing bispecific antibodies and ADCs (including IBI354 FRα ADC) for oncology. Comparable to Zymeworks' ZW191 FRα program and partnership with BeOne Medicines for China/APAC commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zymeworks

Biopharmaceuticals / Oncology Therapeuticszymeworks.com

Zymeworks is a Vancouver-based, publicly traded royalty-driven biotechnology company developing antibody-based therapeutics (bispecifics, ADCs, T cell engagers) for difficult-to-treat cancers, with FDA-approved Ziihera for biliary tract cancer and a pipeline of clinical-stage ADC and TCE assets partnered with Jazz, BeOne, and J&J.

What Zymeworks does

Zymeworks is a Vancouver-headquartered, publicly traded (NASDAQ: ZYME) biotechnology company that has restructured itself as a royalty-driven organization developing antibody-based therapeutics for difficult-to-treat cancers and inflammatory diseases. The company operates a proprietary antibody engineering stack spanning four platforms: Azymetric (heterodimeric bispecific antibody technology clinically validated through the FDA-approved zanidatamab), EFECT (Fc-region effector function modulation), TriTCE (trispecific T cell engagers with conditional CD28 co-stimulation), and ZymeLink ADC payloads (topoisomerase-1 inhibitor, auristatin, and hemiasterlin warheads paired with site-specific conjugation). Its sole commercial product is Ziihera (zanidatamab-hrii), a HER2-directed bispecific antibody approved in the US, EU (conditional), and China for previously treated HER2-positive biliary tract cancer, with a near-term first-line HER2-positive gastroesophageal adenocarcinoma approval decision expected August 25, 2026.

The pipeline includes four clinical-stage assets: ZW191 (FRα-targeting ADC with FDA Fast Track designation for platinum-resistant ovarian cancer, showing 78.6% confirmed ORR in FRα-positive patients in Phase 1), ZW251 (GPC3-targeting ADC for hepatocellular carcinoma), ZW209 (DLL3-targeting trispecific T cell engager for small cell lung cancer), and ZW220 (NaPi2b-targeting ADC). Zymeworks also has ZW1528, an IL-4Rα x IL-33 bispecific for respiratory inflammation/COPD, expanding into non-oncology indications. Partnered assets include pasritamig (CD3 x KLK2 bispecific), which Johnson & Johnson is advancing through Phase 3 for castration-resistant prostate cancer.

Zymeworks generates revenue through tiered royalties (10-20% on Ziihera) and milestone payments (up to $1.36 billion potential from Jazz/BeOne, up to $434 million from J&J) rather than direct commercialization. Three global pharma partners handle manufacturing, regulatory submissions, and sales: Jazz Pharmaceuticals (US/global Ziihera), BeOne Medicines (China/APAC), and Johnson & Johnson (pasritamig globally). The company executed a $250 million non-recourse royalty-backed note financing from Royalty Pharma in March 2026 and authorized a $125 million share repurchase program, holding $403.8 million in cash and equivalents as of Q1 2026 with runway beyond 2028.

Zymeworks firmographics

Firmographics
Name
Zymeworks
Legal name
Zymeworks BC Inc.
Website
https://zymeworks.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
251–500 employees
Short description
Zymeworks is a Vancouver-based, publicly traded royalty-driven biotechnology company developing antibody-based therapeutics (bispecifics, ADCs, T cell engagers) for difficult-to-treat cancers, with FDA-approved Ziihera for biliary tract cancer and a pipeline of clinical-stage ADC and TCE assets partnered with Jazz, BeOne, and J&J.
Ownership category
akta.pro rank

Zymeworks industry classification

Industry
Product category
Biopharmaceuticals / Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody therapeutics
  • Bispecific antibodies
  • Antibody-drug conjugates
  • Oncology drug development
  • Biotechnology licensing

Where Zymeworks is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Zymeworks business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Royalty Revenue from Ziihera: Zymeworks receives tiered worldwide royalties between 10% to 20% on Ziihera (zanidatamab-hrii) sales from Jazz Pharmaceuticals, and tiered royalties up to 19.5% from BeOne Medicines territories. Royalty Pharma holds 30% of Ziihera royalties under the $250M financing deal.
  2. Royalty Revenue from Pasritamig: Zymeworks receives tiered worldwide royalties in the mid-single digit percentages from Johnson & Johnson's pasritamig (JNJ-78278343) sales for castration-resistant prostate cancer.
  3. Milestone Payments: Zymeworks earns milestone payments upon achievement of regulatory approvals and commercial milestones. Up to $1.36B potential milestone payments from Jazz/BeOne for Ziihera across US, EU, Japan, and China. Additional milestones from J&J partnerships and GSK collaborations. A $250M milestone payment from Jazz is expected upon FDA approval in August 2026.
  4. Royalty-Backed Financing: $250M non-recourse royalty-backed note financing from Royalty Pharma, with repayments secured by 30% of worldwide tiered royalties on Ziihera. Royalty Pharma ceases receiving royalties once cumulative payments reach 1.65x the note amount by Dec 31, 2033, or 1.925x at any time thereafter.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Zymeworks product offering

Product offering

Core offering

Zymeworks is a clinical-stage biopharmaceutical company that designs and develops novel antibody-based therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs), for difficult-to-treat cancers. The company uses proprietary platforms such as Azymetric, EFECT, TriTCE, and topoisomerase-1 inhibitor payload technologies to engineer its pipeline candidates (e.g., Ziihera/zanidatamab, ZW191, ZW251, ZW220, ZW209, ZW1528) and licenses these candidates and platforms to large pharmaceutical partners (Jazz Pharmaceuticals, BeOne Medicines, Johnson & Johnson, GSK) for global development and commercialization in exchange for royalties and milestone payments.

Product overview

Zymeworks is a royalty-driven biotechnology company that has transformed from a clinical-stage biotech into a healthcare asset management organization. The company manages a portfolio of licensed products and develops novel multifunctional biotherapeutics. Its core approved product is Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody for biliary tract cancer. The proprietary pipeline includes multiple antibody-drug conjugates (ZW191, ZW251, ZW220) targeting different tumor antigens using topoisomerase-1 inhibitor payloads, and trispecific T cell engagers (ZW209) and bispecific antibodies (ZW1528) for oncology and inflammatory diseases. These programs are supported by proprietary technology platforms including Azymetric (bispecific antibody engineering), EFECT (effector function modulation), TriTCE (T cell engager with costimulation), and ADC payload technologies. The company generates revenue through royalties and milestone payments from partners including Jazz Pharmaceuticals, BeOne Medicines, and Johnson & Johnson.

Differentiator

Problem solved

Functional benefit

Brands

  • Azymetric: Heterodimeric antibody technology platform enabling transformation of monospecific antibodies into multispecific antibodies with alternative target binding formats.
  • EFECT
  • ZymeLink
  • ZW191
  • ZW251

Products and services

  • Ziihera (zanidatamab-hrii) A bispecific HER2-directed antibody approved by the FDA for treating adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Also in development for gastroesophageal adenocarcinoma and other HER2-expressing cancers.
  • ZW191 A folate receptor alpha (FRα)-targeting antibody-drug conjugate using a topoisomerase-1 inhibitor payload (ZD06519) for treatment of advanced solid tumors including ovarian, endometrial, and lung cancers. FDA Fast Track designation granted for platinum-resistant ovarian cancer.
  • ZW251 A glypican-3 (GPC3)-targeting ADC using a topoisomerase-1 inhibitor payload for treatment of hepatocellular carcinoma (HCC).
  • ZW220 A sodium-dependent phosphate transporter 2b (NaPi2b)-targeting ADC using a topoisomerase-1 inhibitor payload for treatment of ovarian, lung, and pancreatic cancers; IND-ready.
  • ZW209 A DLL3-targeting trispecific T cell engager (TriTCE) with conditional CD28 co-stimulation for treatment of small cell lung cancer and other DLL3-expressing cancers.
  • ZW1528 An IL-4Rα x IL-33 bispecific antibody designed to address respiratory inflammation including mixed-type COPD by inhibiting multiple cytokine pathways.
  • JNJ-78278343 (pasritamig) A CD3 x KLK2 bispecific T cell engager being developed and commercialized by Johnson & Johnson for castration-resistant prostate cancer; eligible for up to $434M in milestones plus tiered worldwide mid-single digit royalties.
  • Azymetric Platform A heterodimeric antibody technology enabling engineering of multispecific antibodies that simultaneously bind multiple distinct targets, supporting formats including Fabs, scFvs, and VHHs; available for partnership/licensing.
  • EFECT Platform Effector Function Enhancement and Control Technology enabling modification of antibody Fc region to selectively modulate interactions with Fc-gamma receptors and complement (C1q) to enhance or negate immune responses.
  • TriTCE Co-Stim Platform Trispecific T cell engager platform with integrated conditional cis CD28 co-stimulation providing T cells with signal 1 (CD3) and signal 2 for enhanced safety and antitumor activity; transferable to diverse targeting strategies.
  • Topoisomerase 1 Inhibitor ADC Technology (ZD06519) Camptothecin-based payload specifically designed for ADC use with moderate potency and strong bystander activity, paired with a traceless, plasma-stable, cleavable peptide linker enabling DAR up to 8.

Quantifiable outcome

  • 78.6% confirmed objective response rate in FRα-positive platinum-resistant ovarian cancer patients (ZW191 Phase 1)
  • +5 more outcomes

Companies that use Zymeworks

Customer profile

Segments4 records

Ideal customer profiles1 record

Zymeworks technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Zymeworks partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor, core/flagship and core.

  • GSKminorStrategic or Co-development Partner · 9 June 2020Strategic collaboration for development of bispecific antibodies using Zymeworks' Azymetric platform. Zymeworks eligible for up to $921.8M in potential milestone payments plus tiered worldwide royalties on sales. GSK collaboration achieved $14M milestone in February 2025.
  • Jazz Pharmaceuticalscore/flagshipOEM/ Whitelabel/ Licensing Partner · 28 November 2018Licensing agreement for zanidatamab (Ziihera) where Jazz holds US commercialization rights and pays tiered royalties (10-20%) plus milestone payments up to $1.36B. Jazz confirmed opt-in in December 2022 and is pursuing FDA approval for first-line HER2+ gastroesophageal adenocarcinoma with PDUFA date of August 25, 2026.
  • BeOne Medicines (BeiGene)core/flagshipOEM/ Whitelabel/ Licensing Partner · 28 November 2018Licensing agreement for zanidatamab where BeOne Medicines holds commercialization rights in China and Asia-Pacific territories, paying tiered royalties up to 19.5% of net sales. BeOne received NMPA approval for HER2-high biliary tract cancer in China and is pursuing additional approvals for gastroesophageal adenocarcinoma.
  • Johnson & Johnson (Janssen)coreStrategic or Co-development Partner · 25 October 2017Collaboration for development of bispecific antibodies including pasritamig (JNJ-78278343, CD3 x KLK2) targeting castration-resistant prostate cancer in Phase 3. Zymeworks eligible for up to $434M in milestones and tiered worldwide royalties in mid-single digit percentages. Peak sales opportunity referenced by J&J exceeds $1-5B.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Zymeworks competitors and assessment

Company assessment

Emerging players

  • Pyxis Oncology: Pyxis Oncology develops ADCs and immunotherapies for difficult-to-treat cancers, with a focus on novel payload and linker technology. Comparable to Zymeworks' emerging ADC pipeline with similar target patient populations in solid tumors.
  • Bolt Biotherapeutics: Bolt Biotherapeutics develops immune-stimulating ADCs (ISACs) combining tumor-targeting antibodies with immune agonists. Shares Zymeworks' focus on novel ADC payloads and difficult-to-treat solid tumor indications.
  • Innovent Biologics: Innovent is a Chinese biopharmaceutical company developing bispecific antibodies and ADCs (including IBI354 FRα ADC) for oncology. Comparable to Zymeworks' ZW191 FRα program and partnership with BeOne Medicines for China/APAC commercialization.

Direct peers

  • Mersana Therapeutics: Mersana is a clinical-stage ADC company developing novel payloads and linkers for oncology applications. Directly comparable to Zymeworks' ADC platform (ZW191, ZW251, ZW220) and novel topoisomerase-1 inhibitor payload approach.
  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based therapeutics including toxin conjugates (Bicyclic ADC platform) for oncology, comparable to Zymeworks' ZW191/ZW251 ADC programs. Both companies target solid tumors with novel payload and conjugation approaches.
  • MacroGenics: MacroGenics develops bispecific antibodies and antibody-based therapeutics for cancer, sharing Zymeworks' focus on multispecific antibody platforms. Both companies target oncology with proprietary antibody engineering platforms and similar therapeutic indications including solid tumors.
  • Genmab: Genmab is a leading bispecific antibody developer (Duobody platform) with multiple approved and clinical-stage products including bispecifics partnered with large pharma. Directly comparable to Zymeworks' Azymetric-based bispecific approach and royalty/partnership business model.

Broad incumbents

  • Seagen (Pfizer): Seagen (acquired by Pfizer for $43B) is a leading ADC company with multiple approved products (Adcetris, Padcev, Tukysa, Tivdak) and represents an established incumbent in the ADC space comparable to Zymeworks' ADC pipeline focus.
  • ImmunoGen (AbbVie): ImmunoGen (acquired by AbbVie) pioneered ADC technology and markets Elahere, an FRα-targeting ADC for platinum-resistant ovarian cancer. Directly competes with Zymeworks' ZW191 in the same indication with similar target and mechanism.
  • Daiichi Sankyo: Daiichi Sankyo developed Enhertu (trastuzumab deruxtecan), the leading HER2 ADC that competes with Ziihera in HER2-positive cancers. Represents a broad incumbent with overlapping HER2 oncology franchise relevant to Zymeworks' partnered bispecific asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Zymeworks social profiles

Digital presence

Zymeworks financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zymeworks leadership team

Management profile

Number of profiles

Profiles10 records

Zymeworks funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zymeworks M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zymeworks

What does Zymeworks do?

Zymeworks is a clinical-stage biopharmaceutical company that designs and develops novel antibody-based therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs), for difficult-to-treat cancers. The company uses proprietary platforms such as Azymetric, EFECT, TriTCE, and topoisomerase-1 inhibitor payload technologies to engineer its pipeline candidates (e.g., Ziihera/zanidatamab, ZW191, ZW251, ZW220, ZW209, ZW1528) and licenses these candidates and platforms to large pharmaceutical partners (Jazz Pharmaceuticals, BeOne Medicines, Johnson & Johnson, GSK) for global development and commercialization in exchange for royalties and milestone payments.

Is Zymeworks a public or private company?

Zymeworks is a public company. It is classified as public and is currently operating.

When was Zymeworks founded?

Zymeworks was founded in 1999. It employs 251 to 500 people.

Where is Zymeworks based?

Zymeworks is headquartered in Vancouver, Canada, in the North America region.

How does Zymeworks make money?

Four revenue lines are on record. Royalty Revenue from Ziihera is the primary driver. The others are royalty Revenue from Pasritamig, milestone Payments and royalty-Backed Financing.

Who are Zymeworks's main competitors?

Emerging players on record are Pyxis Oncology, Bolt Biotherapeutics and Innovent Biologics. Direct peers are Mersana Therapeutics, Bicycle Therapeutics, MacroGenics and Genmab. Broad incumbents are Seagen (Pfizer), ImmunoGen (AbbVie) and Daiichi Sankyo.

Does Zymeworks have an API?

No public API is recorded for Zymeworks.

What industry is Zymeworks in?

Zymeworks's product category is Biopharmaceuticals / Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comZymeworks at Jefferies Global Healthcare Conference: pipeline breadth and capital disciplineZymeworks outlined its pipeline and capital strategy at the Jefferies Global Healthcare Conference, highlighting zanidatamab's second interim OS data and a $55 million Roche deal for ZW209. The company has repurchased 17% of shares since 2024 and faces late-stage trial risks. Key catalysts include the zanidatamab pan-tumor study by December 2026 and pasritamig's Phase III readout in 2027.The future of tradingZymeworks Chief Scientific Officer Paul Andrew Moore Sells $1.04 Million in Common SharesZymeworks Chief Scientific Officer Paul Andrew Moore sold 39,741 common shares on Nov. 13, 2026, generating $1.04 million. He also exercised 25,000 options at $5.82 per share. After the transactions, he held 33,756 shares and 175,000 options.TradingViewZymeworks Authorizes Up to $200 Million in Share Repurchases Through 2028Zymeworks authorized a second 2026 share repurchase program of up to $200 million, with about $140 million expected through 2028. The company may adjust the pace based on market conditions and cash flow, and funding comes from the balance sheet and near-term cash flows.TradingViewZymeworks Chief Scientific Officer Sold Shares Worth Over $1.0MZymeworks Chief Scientific Officer Paul Andrew Moore sold 39,741 shares in three transactions on November 13, 2026, at weighted average prices of $26.14, $26.09, and $26.04 per share. The sales totaled $1,035,961, leaving him with 33,756 shares.The future of tradingZymeworks board authorizes $200 million share repurchase programZymeworks' board authorized a second 2026 share repurchase program covering up to $200 million of common stock through 2028. Repurchases are expected to begin before year-end, with approximately $140 million in total spending planned. The pace will depend on market opportunities, cash flow, and potential contributions to long-term shareholder returns.TradingViewZymeworks authorizes up to $200M in share repurchasesZymeworks' board authorized a second 2026 share repurchase program of up to $200M, with about $140M in buybacks expected through 2028. The company plans to begin repurchases before the end of 2026, funded by its balance sheet and expected cash flows, including $55M in upfront fees from its Roche collaboration and a potential $100M milestone payment tied to TRELEGY ELLIPTA sales in Q1 2027.American Banking and Market NewsFisher Asset Management LLC Acquires 537,837 Shares of Zymeworks Inc. $ZYMEFisher Asset Management increased its Zymeworks stake by 759.9% in Q3, holding 608,612 shares worth $16.12 million. Analysts rate the stock a Moderate Buy with a consensus target of $43.25. Zymeworks reported Q3 EPS of $2.28, beating estimates, with revenue up 828.7% year-over-year.American Banking and Market NewsTruist Financial Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) StockTruist Financial raised its Zymeworks price target to $36 from $35, keeping a Buy rating. The stock opened at $29.07, with a consensus price target of $42.67. Zymeworks reported Q3 EPS of $2.28, beating estimates, and revenue of $512.92 million, up 828.7% year-over-year.Investing.comZymeworks at stifel 2026 healthcare conference: royalties, deals and growthZymeworks presented at the Stifel 2026 Healthcare Conference, highlighting the commercial launch of zanidatamab in HER2-expressing gastric cancer with an eight-month median overall survival benefit. Jazz's peak sales guidance of $3–5 billion implies $500–900 million in annual royalty income for Zymeworks. The company plans to allocate capital opportunistically among R&D, buybacks, and acquisitions.Quiver Quantitative$ZYME stock is down 8% today. Here's what we see in our data. | ZYME Stock NewsZYME stock fell 8% today, with $11.98 million in trading volume. Insiders sold 13,832 shares, and hedge fund activity shows 90 institutions added while 101 reduced positions. Analysts' median price target is $37.0.